Table 1.
Clinical and Pathologic Comparison Between HCC Patients With Low and High CD26 Expression
| Factors | Low CD26 expression (n = 15) | High CD26 expression (n = 26) | P value |
|---|---|---|---|
| Age (y) | 64.7 ± 8.0 | 66.2 ± 8.5 | .515 |
| Gender (M/F) | 10/5 | 19/7 | .664 |
| Platelet count (×104/mL) | 13.8 ± 5.0 | 15.5 ± 5.1 | .401 |
| AST (IU/L) | 33.3 ± 15.6 | 45.1 ± 28.9 | .198 |
| ALT (IU/L) | 28.5 ± 19.9 | 39.4 ± 29.4 | .159 |
| γ-GT (IU/L) | 42.7 ± 22.6 | 77.9 ± 81.8 | .261 |
| Total bilirubin (mg/dL) | 0.75 ± 0.30 | 0.68 ± 0.31 | .388 |
| Albumin (g/dL) | 4.06 ± 0.44 | 3.98 ± 0.41 | .684 |
| Prothrombin time (%) | 96.7 ± 13.2 | 89.8 ± 12.7 | .160 |
| HbA1c (%) | 6.44 ± 0.95 | 6.49 ± 0.94 | .416 |
| Alpha-fetoprotein (ng/mL) | 19.3 ± 29.8 | 114.0 ± 187.8 | .012 |
| Des-γ-carboxy prothrombin (mAU/mL) | 425.1 ± 1319.0 | 508.9 ± 22,121.6 | .097 |
| Etiology (HBV/HCV/alcohol/other) | 7/7/0/1 | 4/14/6/2 | .071 |
| Non-tumor tissue (chronic hepatitis/cirrhosis) | 8/7 | 13/13 | .837 |
| Tumor size (mm) | 25.5 ± 15.0 | 29.9 ± 27.4 | .745 |
| Tumor number (multiple/single) | 2/13 | 7/19 | .311 |
| Portal vein invasion (+/−) | 2/13 | 8/18 | .211 |
| UICC staging (I/II/III) | 10/4/1 | 5/13/8 | .008 |
| Capsule formation of tumor (+/−) | 8/7 | 19/7 | .199 |
| Cancerous infiltration of capsule (+/−) | 3/12 | 14/12 | .034 |
| Differentiation (well/moderate/poor) | 9/5/1 | 0/22/4 | <.001 |
| Ki67 labeling index | 0.065 ± 0.048 | 0.189 ± 0.090 | <.001 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, gamma-glutamyl transferase; HbA1c, glycosylated hemoglobin; HBV, hepatitis B virus; UICC; Union for International Cancer Control.